Business
BNCM and DELEX Healthcare Group, Inc. Announce their Expansion Plans to Solidify Market Presence
BNCM and DELEX Healthcare Group, Inc. Announce their Expansion Plans to Solidify Market Presence.
About this update from Bounce Mobile Systems, Inc.
[{"type":"text","content":"Bounce Mobile Systems Inc. (BNCM) and Delex Healthcare Group, Inc. (DELEX), a profitable and fast-growing healthcare and pharmaceutical company, today announce their expansion plans designed to solidify the market position and drive the future growth of DELEX.With DELEX’s successful union and strategic merger alliance with Bounce Mobile Systems Inc. (BNCM), the shared objective of fostering a better market presence, while continuing to meet the gaps of critical care patients with accessible medical treatments, presents an enticing opportunity for interested investors, shareholders, and partners seeking opportunities in the growing Southeast Asia healthcare industry.Visionary LeadershipWith 15 years of business operations, the company, guided by remarkable leaders with extensive experience, managerial and entrepreneurial skills, and knowledge in the pharmaceutical and medical industries, has achieved a significant share of the impressive Philippine pharma and medical device market, valued at approximately US$5.05 billion1,2. Even as a relatively young player in the industry, this achievement solidifies their position as strong leaders in healthcare. The leaders’ innovative approaches and strategic insights have set the organization on a path for long-term growth and prosperity.Key Highlights of the Expansion Plan DELEX plans to develop more product ranges, secure more distribution rights, expand its worldwide distribution networks, and invest in manufacturers of healthcare products and providers of healthcare services. The expansion plans are multi-faceted, involving a range of strategic activities designed to both capture new markets and improve its current services. Key components of the expansion strategy include:a. Introduce New Product Lines and Distribution Rights DELEX plans to continue developing and obtaining patents for more medical and critical care items. This will be able to broaden its product line to include a range of products for critical care and the treatment of major illnesses such as cardiovascular disease, diabetes, cancer, COVID-related diseases, immunity, and anti-aging, including stem cells and probiotics. Currently, it has twenty-five (25) company-owned brands, 20 (twenty) of which are granted trademarks by the Intellectual Property Office of the Philippines (IPOPH)3. Note that Delex has two (2) subsidia...